View from the Thoraxcenter: ACC 22 Late-breaking Science Preview

Published: 25 Mar 2022

  • Views:

    Views Icon 1321
  • Likes:

    Heart Icon 5
Average (ratings)
No ratings
Your rating

In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022

Trials covered in detail include:

00:39: PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients With Acute Myocardial Infarction: A Double-blind, Placebo-controlled, Randomized Trial (NCT03067844)

03:20: VALOR-HCM: Mavacamten as an Alternative to Surgical Septal Myectomy or Alcohol Ablation in Patients with Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy (NCT04349072)

05:04: Results of the EDIT-CMD Randomized Clinical Trial: Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in Angina and Nonobstructive Coronary Arteries (NCT04777045)

06:57: PROMPT-HF: A Cluster-Randomized PRagmatic Trial Aimed at ImprOving Use of Guideline Directed Medical Therapy in OutPatienTs with Heart Failure (NCT04514458)

08:58: The FAME 3 Trial: Quality of Life After Fractional Flow Reserve-guided Stenting Compared With Coronary Bypass Surgery (NCT02100722)

11:21: The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis (NCT03317002)

13:25: Results From the PARTITA Trial: Catheter Ablation of Ventricular Tachycardia After the First Implantable Cardioverter Shock (NCT01547208)

15:29: Insights From the Corevalve US Pivotal and SURTAVI Trials: Five-year Incidence, Timing and Predictors of Hemodynamic Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses (NCT01586910)

17:15: A Randomized ADAPT-TAVR Trial: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis and Cerebral Thromboembolism after Transcatheter Aortic-valve Replacement (NCT03284827)

19:47: 3-year Efficacy Outcomes from the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation on Blood Pressure Reduction in Patients on Antihypertension Medications (NCT02439775)